Thursday, October 8, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 27, 2026

Dow confirms correction as traders worry about war

View original at sg.finance.yahoo.com
Dow confirms correction as traders worry about war By Noel Randewich March 27 (Reuters) - The Dow Jones Industrial Average fell 1.7% on Friday as investors worried about the global economic ‌impact of the war in Iran, leaving the blue-chip index down ‌10% from its record high close on February 10 and confirming it has…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Investors are weighing whether the downturn is a temporary dip similar to the recovery that followed the 2025 selloff, or the start of a sustained period of risk tied to the war

    60% confidence

  • The Dow Jones Industrial Average has confirmed it has been in a correction since its record high close on February 10, now down 10% from that level

    60% confidence

  • Sky-high oil prices have sparked fears of inflation, with traders expecting the Federal Reserve to be more likely to raise interest rates by year-end than cut rates

    60% confidence

Data points we hold from this source

Dow Jones Industrial Average · drawdown from peak-10 percent
Dow Jones Industrial Average · decline since iran war-7 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,362 source documents archived
Query this data → isubstrate.com
Dow confirms correction as traders worry about war — Source | Via News | ViaNews Market